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Abstract 
Meropenem is one of the most commonly used antibacterial agents with relatively few side 
effects. Serious adverse reactions reported with meropenem are rare with an incidence of 1 
%. Recently we came across two rare adverse effects of meropenem in one patient with 
acute renal failure. There was pancytopenia and sepsis, respectively. To the best of our 
knowledge, a only few cases have been reported in the literature that document an 
association between meropenem administration and pancytopenia, and about half of these 
cases were sepsis. With the use of meropenem becoming more widespread, these two rare 
but fatal complications of meropenem should be borne in mind.  
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Meropenem is an ultra-broad spectrum injectable 
antibiotic used to treat a wide variety of 
infections, including meningitis and pneumonia 
[1]. It is a beta-lactam drug and belongs to the 
subgroup of carbapenem, similar to imipenem 
and ertapenem. It gained United States Food 
and Drugs and Administration (FDA) approval in 
July 1996. It penetrates well into many tissues 
and body fluids including the cerebrospinal fluid, 
bile, heart valves, lung and peritoneal fluid. The 
spectrum of action includes many Gram-positive 
and Gram-negative bacteria (including 
Pseudomonas) and anaerobic bacteria. The 
overall spectrum is similar to imipenem although 
meropenem is more active against 
Enterobacteriaceae and less active against 
Gram-positive bacteria [2]. The most common 
adverse effects are diarrhea (4 – 5 %), nausea 
and vomiting (1 – 4 %), injection-site 
inflammation (2 %), headache (2 %), rash (2 – 3 
%), and thrombophlebitis (1 %). Rarely, it has 
been associated with pancytopenia, sepsis, 
septic shock, toxic epidermal necrolysis, renal 
damage and acute renal failure [3]. We report a 
case of meropenem induced pancytopenia and 




Our patient is a 78-year old female with left hip 
fracture which occurred as a result of a fall. Total 
hip replacement surgery had been done by an 
orthopaedic clinic. As a result of the prothesis 
dislocation, she was sent to the orthopaedic 
clinic of our hospital. Following evaluation, the 
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orthopaedic doctors decided to remove the 
prothesis because there was infection and 
relaxation in prothesis. After removing the 
prothesis, she was treated with 3 mg/kg/day 
dose intravenous (iv) gentamicin, for 10 days. 
Due to pain, doctors gave her intramuscular 
diclofenac sodium injection twice a day. The 
patient presented with a reduction in the amount 
of urine, intermittent nausea and vomiting, ten 
days after the intake of gentamicin and non-
steroidal antiinflammatory drug. As a result of the 
elevation of creatinine levels, patient was 
referred to us. The patient developed acute renal 
failure because of the nephrotoxic agents which 
had been used for treatment. Therefore, 
gentamicin was discontinued and she was 
placed on ıv piperasilin tazobactam 2.25 mg 
three times daily, after which we took over 
management.  
 
There was no other systemic disease in the 
patient. Her general condition was normal and 
conscience was clear. There was no problem 
about orientation and she was cooperative. Her 
vital signs were normal. Şhe was obese and her 
conjunctival sac and skin were pale. There were 
crackles at bilateral basal region of the lung. 
There was considerable (+++) edema on the left 
proximal part of the femur due to surgery. There 
was also pre-tibial pitting edema on bilateral 
lower extremities. Laboratory test results 
obtained (along with normal range of values) are 
shown in Table 1. For her arterial blood 
parameters, pH was 7.29 whule HCO3
- was 13 
(normal range = 22 - 26). There was no 
proteinuria. She was given intravenous fluid by 
close monitoring of blood pressure and 
peripheral venous pressure. We used gave 
diüretic when necessary. After a few days, the 
creatinine levels of the patient began to decline. 
The patient developed purpuric and itchy lesions 
all over body six days after the intake of 
piperacillin tazobactam.  
 
Patient was referred to the dermatology clinic 
and her antibiotic was changed to iv meropenem 
1 g two times daily. We dressed her wound daily 
and took wound culture everyday. On the 7th day 
of her admission, Acinetobacter baumonnii and 
methicillin-resistant coagulase-negative Staphy-
lococci (MRCNS) were found on her wound 
cultures. The patient was then referred to the 
infectious diseases clinic. The patient was kept in 
isolation with all aseptic precautions. In 
accordance with the advice of infectious 
diseases clinic, we began treatment with 
doripenem, tigesycline and rifampicin. 
Meropenem treatment was commenced on the 
second day. One day after the growth of the 
bacteria, her fever was about 39 oC. Her blood 
pressure was 80/40 mmHg brachial and her 
pulse was 110/min. Her new laboratory test 
results showed the following:  white blood cells 
1000 cell/µl, hemoglobin 6.6 g/dl, platelet count 
97000 cell/µl, international normalized ratio (INR) 
1.53, blood urea nitrogen (BUN) 74 mg/dl, 
creatinine 3 mg/dl, sodium 152 mEq/l, potassium 
3.6 mEq/l, calcium 5.5 mEq/l, phosphate 6.1 
mEq/l, C-reactive protein :159 mg/L. The patient 
developed pancytopenia and sepsis three days 
after intake of meropenem. Two days after the 
growth of the bacteria, she died.  
 
Table 1:  Laboratory findings before and after 










WBC 7600 1000 4300 - 
10300 
cell/µl 
Hb 8.3 6.6 13.6 - 
17.2 g/dl 
Plt 186000 97000 156000 - 
373000 
cell/µl 
BUN 94 74 5 - 23 
mg/dl 
Cre 9.2 3 0.81 - 
1.44 
mg/dl 
Na 136 152 135 - 145 
mEq/l 
K 3.9 3.6 3.5 - 4.5 
mEq/l 
Ca 6.8 5.5 8.8 - 10.8 
mEq/l 
P 8.5 6.1 3.0 - 4.5 
mEq/l 
UA 11 - 2.4 – 7.0 
mg/dl 
CRP 72 159 0 - 10 
mg/L 
ESR 50 mm/h - 0 - 20 
mm/h 
INR 1.12 1.53 0.9 - 1.2 
 
Abbreviations: WBC = white blood cell, Hb = hemoglobin, 
Plt = platelet, BUN = blood urine nitrogen,  
Cre = creatinine, Na = sodium, K  potassium, Ca = calcium, P 
= phosfate, UA = uric acid, CRP = C-reactive protein, ESR = 
erythrocyte sedimentation rate, INR = international 




Pancytopenia is a rare life-threatening 
complication of meropenem [2]. The overall 
incidence of non-chemotherapy drug-induced 
agranulocytosis ranges from 2.6 to 10 cases per 
million patients exposed to the drugs per year [4]. 
Neutropenia usually leads to severe sepsis, 
requiring iv broad-spectrum antibiotic therapy, as 
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in the case of our patient. The severity of 
neutropenia and its duration may also impact 
negatively on the outcome. Hemopoietic growth 
factors have been shown to shorten the duration 
of neutropenia in drug-induced agranulocytosis. 
With appropriate management, the mortality rate 
is around 5 % [4]. 
 
In the literature, a study of pancytopenia among 
people who take meropenem hasbeen reported 
in eHealthMed based on 87 reports from FDA 
and user communities [2]. Fifty nine percent of 
people who had pancytopenia while taking 
meropenem were male and 38 % of them were > 
60 years old. Most of these 87 patients also had 
Pseudomonas infection. Another study of  
bacterial sepsis among people who take 
meropenem, also in eHealthMe and based on 7 
reports from FDA and user communities reported 
that 57 % of those who had bacterial sepsis while 
taking meropenem were female and 28 % of 
them were over 60 years old. Most co-used 
drugs for these patients in these studies were 
vancomycin, tacrolimus, methotrexate and 
neupogen [2]. 
 
In our patient, we came across two rare life-
threatening complications of meropenem, 
namely, pancytopenia and sepsis. There have 
been reports in the past regarding the fatal 
outcome of meropenem-induced pancytopenia 
and sepsis. Our patient died but we do not know 
exactly whether meropenem was the cause of 
her death since şhe also had acinetobacter and 
MRCNS infections. However, the literature, 
derived mostly from FDA reports, shows that 





We believe that with the use of meropenem 
becoming more widespread, these two rare but 
fatal complications of meropenem should be 
borne in mind while using this drug. Clinicians 
should also take into consideration the important 
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